Form 4: Ptc Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Mark Elliott Boulding, EXEC. VP AND CLO of Ptc Therapeutics, Inc., sold 2,073 shares of common stock on October 5, 2026.
Summary
- Option exercise/conversion: acquired 1,638 Common Stock at $39.42 ($64,570) on October 5, 2026; holds 106,910 after (Direct).
- Open-market sale: disposed of 1,638 Common Stock at $64.03 ($104,881) on October 5, 2026; holds 105,272 after (Direct).
- Option exercise/conversion: acquired 435 Common Stock at $39.42 ($17,148) on October 6, 2026; holds 105,707 after (Direct).
- Open-market sale: disposed of 435 Common Stock at $64.16 ($27,910) on October 6, 2026; holds 105,272 after (Direct).
- Option exercise/conversion: disposed of 1,638 Stock Option (Right to Buy) on October 5, 2026; holds 2,894 after (Direct).
- Option exercise/conversion: disposed of 435 Stock Option (Right to Buy) on October 6, 2026; holds 2,459 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $132,791 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Mark Elliott Boulding — Officer (EXEC. VP AND CLO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-05 | Option exercise/conversion | Common Stock | 1,638 | $39 | $64.6K | 106,910 |
| 2026-10-05 | Open-market sale | Common Stock | 1,638 | $64 | $104.9K | 105,272 |
| 2026-10-06 | Option exercise/conversion | Common Stock | 435 | $39 | $17.1K | 105,707 |
| 2026-10-06 | Open-market sale | Common Stock | 435 | $64 | $27.9K | 105,272 |
| 2026-10-05 | Option exercise/conversion | Stock Option (Right to Buy) | 1,638 | — | — | 2,894 |
| 2026-10-06 | Option exercise/conversion | Stock Option (Right to Buy) | 435 | — | — | 2,459 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-05 | Option exercise/conversion (1,638 shares) |
| 2026-10-05 | Open-market sale (1,638 shares) |
| 2026-10-06 | Option exercise/conversion (435 shares) |
| 2026-10-06 | Open-market sale (435 shares) |
| 2026-10-05 | Option exercise/conversion (1,638 shares) |
| 2026-10-06 | Option exercise/conversion (435 shares) |
Keywords
insider transaction, Form 4, PTCT, PTC THERAPEUTICS, INC., bearish, Mark Elliott Boulding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.